Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 6/20 | 0.37 |
| ▸ | CDA | P32320 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.34 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.34 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.34 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 4/20 | 0.33 |
| ▸ | PNP | P00491 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HEXB | P07686 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18079907 | 0.88 | PYGL (0.44) | PYGLCDAMAPTSLC5A2PNP | |
| SCHEMBL16631698 | 0.88 | PYGL (0.44) | PYGLCDAMAPTSLC5A2PNP | |
| SCHEMBL16631245 | 0.86 | PYGL (0.38) | PYGLCDAMAPTSLC28A1SLC28A2 | |
| SCHEMBL16631834 | 0.83 | PYGL (0.36) | PYGLCDAMAPTSLC5A2OGA | |
| SCHEMBL16631829 | 0.82 | PYGL (0.34) | PYGLCDAMAPTSLC28A1SLC28A2 | |
| SCHEMBL16631174 | 0.82 | PYGL (0.35) | PYGLCDAMAPTSLC28A1SLC28A2 | |
| SCHEMBL16631268 | 0.79 | CDA (0.35) | PYGLCDAMAPTOGAPNP | |
| SCHEMBL16631523 | 0.78 | PYGL (0.37) | PYGLCDAMAPTSLC5A2OGA | |
| SCHEMBL16631577 | 0.77 | SLC28A1 (0.40) | CDAMAPTSLC5A2SLC28A1SLC28A2 | |
| SCHEMBL16631306 | 0.75 | PYGL (0.44) | PYGLCDAMAPTSLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2015051173-A2 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160264614-A1 | POLYNUCLEOTIDE MOLECULES AND USES THEREOF | POLRMT, POLN, NSUN3 | PYGL 649/4885CDA 200/4885MAPT 3290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.